Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.

1 Oct 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

Omeros announces positive data from OMS824 Phase 1 clinical trial

Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.

12 Sep 2013

Wake Forest Baptist conducts $24 million project to accelerate development of new therapies

Whether it's the Ebola virus or Sarin and Ricin, a key to responding to chemical or biological attacks is having effective antidotes at the ready. To accelerate the development of new therapies, Wake Forest Baptist Medical Center's Institute for Regenerative Medicine is leading a unique $24 million federally funded project to develop a "body on a chip" that will be used to develop these countermeasures.

12 Sep 2013

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease.

10 Sep 2013

Research offers focused explanation for cardiac arrest predilection for morning hours

Evidence from people with heart disease strongly supports the existence of the molecular link first discovered in laboratory mice between the body's natural circadian rhythms and cardiac arrest or sudden cardiac death (SCD) - the No. 1 cause of death in heart attacks, a scientist said here today.

10 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Elan Corporation, plc (NYSE: ELN) announced today the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

3 Sep 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Macrogenics Received $10M Milestone From Servier

...

22 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

Pharmacokinetics News and Research

Further Reading

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros announces positive data from OMS824 Phase 1 clinical trial

Wake Forest Baptist conducts $24 million project to accelerate development of new therapies

Rhythm Awarded $1.35M From Michael J. Fox Foundation

Roche Signs Up To $422.5M Collaboration With Inovio

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Research offers focused explanation for cardiac arrest predilection for morning hours

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

FDA grants Priority Review designation to sNDA for Nexavar tablets

Macrogenics Received $10M Milestone From Servier

FDA: New drug Tivicay approved to treat HIV-1 infection

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News